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Abstract
 
CD22 is a B cell–specific transmembrane protein of the Siglec family. It binds specifically to
 
 
 
2,6-linked sialic acid (Sia) residues, which are also present on glycoproteins on the B cell sur-
face. CD22 acts as a negative regulator in B cell receptor–mediated signaling by recruitment of
Src homology 2 domain–containing tyrosine phosphatase (SHP)-1 to its intracellular tail. To
analyze how ligand-binding of CD22 influences its intracellular signaling domain, we designed
synthetic sialosides as inhibitors for the lectin domain of CD22. One of these compounds in-
hibited binding of human CD22-Fc to target cells over 200-fold better than Sia and was highly
selective for human CD22. When Daudi cells or primary B cells were stimulated with anti-
immunoglobulin (Ig)M in presence of this sialoside inhibitor, a higher Ca
 
2
 
 
 
 response was ob-
served, similar to CD22-deficient B cells. Accordingly, a lower tyrosine-phosphorylation of
CD22 and SHP-1 recruitment was demonstrated in presence of the sialoside. Thus, by interfer-
ing with ligand binding of CD22 on the B cell surface, we have shown for the first time that
the lectin domain of CD22 has a direct, positive influence on its intracellular inhibitory do-
main. Also, we have developed a novel low molecular weight compound which can enhance
the response of human B cells.
Key words: B lymphocytes • CD22 • Siglecs • sialic acid • Ca
 
2
 
 
 
 ﬂux
 
Introduction
 
CD22 is a B cell–specific transmembrane protein of the Ig
superfamily with seven Ig-like domains. CD22 seems to
have two distinct functions. First, it is associated with the B
cell receptor (BCR) and inhibits the BCR signal, as has
been demonstrated by characterization of CD22-deficient
mice (1–4). B cells of these mice show an increased Ca
 
2
 
 
 
response when stimulated by anti-IgM. The inhibitory effect
of CD22 is due to phosphorylation of three Ig-like ty-
rosine-based inhibitory motifs on its intracellular tail upon
BCR stimulation. This results in recruitment and activation
of Src homology 2 domain–containing tyrosine phos-
phatase (SHP)-1 (5), a tyrosine phosphatase which inhibits
several signaling pathways, and binding of other intracellu-
lar proteins with unknown significance (for a review, refer-
ences 6 and 7). Second, CD22 has properties of a lectin,
belongs to a family of adhesion molecules, the Siglecs (sialic
acid [Sia]–binding Ig-like lectins) and is also referred to as
Siglec-2 (7, 8). CD22 has a high specificity for Sia in the
 
 
 
2,6-linkage (2,6Sia) (9, 10). When CD22 is transfected
into heterologous cells, which do not display N-glycans
with 2,6Sia, it can mediate Sia-dependent binding to vari-
ous cell types (11, 12). In comparison, peripheral B cells
usually display high levels of 2,6Sia on the cell surface, and
CD22 is bound in cis on the majority of these cells (13, 14).
Nevertheless, CD22 controls the homing of recirculating B
cells back to the bone marrow by binding to ligands which
are expressed on sinusoidal endothelium (15).
So far, it is not clear how these two apparently distinct
functions of CD22 are linked. Binding to ligands on the B
cell surface in cis may affect the subcellular localization and
accessibility of the intracellular domain of CD22 and
thereby control its inhibitory function. Solution of the 3-D
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structure of the first Ig domain of sialoadhesin (Sn, Siglec-1)
in a cocrystal with 2,3 sialyllactose showed that all molecu-
lar contacts of conserved amino acids of the ligand-binding
site are to the carbohydrate residues (16). Molecular mod-
eling of a CD22 structure, as well as site-directed mutagen-
esis suggest a similar Sia binding site as in Sn (17). There
is so far no evidence for protein epitopes contributing to
CD22 ligand binding. Models trying to predict the influ-
ence of the ligand-binding domain on signaling have sug-
gested that CD22 is sequestered away from the BCR by
2,6Sia carrying proteins, thereby releasing the BCR from
the CD22 inhibition (18). Alternatively, Sia-binding could
directly mediate CD22 interaction to the BCR (6) or the
ligand-binding domain could have no influence on signal-
ing at all.
We have addressed the role of the ligand-binding do-
main of CD22 by development of a new class of Sia analogs
as artificial high affinity Siglec ligands. One of these sialo-
sides could efficiently inhibit 2,6 Sia binding of human
CD22 with a high specificity. The effect of this potent in-
hibitor sialoside on B cell signaling is described here.
 
Materials and Methods
 
Fc-Chimaera Inhibition Assay with Sia Analogs
 
Fc-Chimeras.
 
Fc-chimeras containing the NH
 
2
 
-terminal three
domains of human CD22 (hCD22
 
d1–3
 
-Fc) (19), murine CD22
(mCD22
 
d1–3
 
-Fc), or murine Sn (Sn
 
d1–3
 
-Fc) were produced in
COS cells as described previously (9).
 
Synthetic Sialosides. 
 
 The synthesis of Methyl-
 
 
 
2-Neu5Ac
(Me-Neu5Ac) has been described previously (20). Methyl-a-9-N-
(biphenyl-4-carbonyl)-amino-9-deoxy-Neu5Ac (BPC-Neu5Ac)
and Methyl-a-9-N-(biphenyl-4-acetyl)-amino-9-deoxy-Neu5Ac
(BPAc-Neu5Ac) were prepared by acylation of methyl-
 
 
 
-9-
amino-9-deoxy-Neu5Ac, obtained by a Mitsunobu reaction-based
synthesis, using activated BPC and BPAc, as will be described in
detail elsewhere. All these compounds were fully characterized by
elemental analyses, MS and 
 
1
 
H-NMR spectroscopy.
 
Binding Assay.
 
Purified Fc-chimeras were labeled with carrier
free Na
 
125
 
I (Amersham Pharmacia Biotech) and complexed with
equimolar concentrations of anti–human IgG (Biodesign) to be
used in binding assays with glutardialdehyde-fixed murine my-
eloma cells AG8 or human erythrocytes as described previously
(9). For inhibition assays 10 
 
 
 
l radio-iodinated Fc-chimeras were
mixed with an equal volume of the sialoside, pH 7.5, and incu-
bated for 1 h at 4
 
 
 
C before 10 
 
 
 
l cells were added. After an over-
night incubation at 4
 
 
 
C, the cells were washed and the bound ra-
dioactivity was quantified. The 50% inhibition concentrations
(IC
 
50
 
) and the relative inhibitory potencies (rIP) were calculated
as described previously (21).
 
Cellular Inhibition Assays with Sia Analogs
 
Daudi cells (human B cell line) or mouse splenic B cells were
treated with sialidase (from 
 
A. ureafaciens
 
; Roche Laboratories) at
37
 
 
 
C. These cells or untreated controls were preincubated with
sialosides on ice for 10 min. Then cells were stained with
NeuGc2,6-PAA-bio (Neu5Gc
 
 
 
2–6Gal
 
 
 
1–4GlcNAc-O(CH
 
2
 
)
 
2
 
-
PAA) (unpublished results). This was followed by streptavidin-PE
staining (plus B220-FITC for mouse cells). Cells were analyzed
by flow cytometry.
 
Measurement of Intracellular Ca
 
2
 
 
 
 Mobilization
 
Daudi cells were loaded with 4.5 
 
 
 
M Indo-1 plus 0.003% plu-
ronic F-127 (both Molecular Probes) in RPMI 1640 with 1%
FCS for 45 min at 37
 
 
 
C. Primary human lymphocytes were pre-
pared from blood by Ficoll-Paque (Amersham Pharmacia Bio-
tech) purification of mononuclear cells. These were Indo1-loaded
similar to Daudi and then stained on ice with anti–CD20-FITC.
Both types of cells were washed and preincubated for 5 min on
ice with or without Sia analogs. The baseline Ca
 
2
 
 
 
 concentration
(proportional to the FL5 to FL4 ratio) was recorded at 37
 
 
 
C and
then 2 
 
 
 
g/ml anti-IgM (clone BU.1; The Binding Site) was
added. For primary lymphocytes, B cells were gated as CD20-
positive and Ca
 
2
 
 
 
 responses were analyzed in this gate. The stain-
ing antibody had no effect on Ca
 
2
 
 
 
, as controlled by unstained
cells. Increases in intracellular free Ca
 
2
 
 
 
 were recorded in real
time with the use of a FACSvantage™ (Becton Dickinson).
 
Immunoprecipitation of CD22
 
6 
 
 
 
 10
 
6
 
 Daudi cells per immunoprecipitation were preincu-
bated in 70 
 
 
 
l on ice for 5 min with the indicated Sia analogue.
Cells were stimulated after filling up with prewarmed RPMI
1640 medium to 1 ml at 37
 
 
 
C for the indicated time points by
adding 2 
 
 
 
g/ml anti-IgM antibody (BU.1). Cells were lysed in
ice-cold NP-40 lysis-buffer containing protease inhibitors. Anti-
CD22 (Dako) and anti-Vav (Santa Cruz Biotechnology, Inc.)
were added together for immunoprecipitation. Precipitates were
resolved by SDS-PAGE and analyzed by immunoblotting with
anti–phospho-tyrosine (clone 4G10), anti–SHP-1, and anti-Vav
(all UBI). Reblotting was done with anti-CD22 (Santa Cruz Bio-
technology, Inc.).
 
Results
 
Siglecs bind their ligand Sia with low affinity (8). Based
on the crystal structure of Sn, complexed with 2,3 sialyllac-
tose, synthetic sialosides were prepared with different sub-
stituents at the C9 of Me-Neu5Ac. These compounds
were designed to allow additional interactions mainly with
hydrophobic areas observed in the crystal structure of Sn to
increase the affinity. About 50 such compounds were syn-
thesized and used in hapten inhibition assays to determine
their rIP (unpublished data). One of these compounds,
BPC-Neu5Ac, had an 
 
 
 
200-fold rIP for human CD22
when Me-Neu5Ac was used as a reference (Fig. 1),
whereas several compounds with very similar structures,
such as BPAc-Neu5Ac, bound much more weakly. Inter-
estingly, this high rIP of BPC-Neu5Ac was not observed
with murine CD22 (mCD22) or Sn. In contrast, BPAc-
Neu5Ac was a more potent inhibitor for mCD22 than
BPC-Neu5Ac (Table I).
To test the specificity of the synthetic sialosides also for
cellular CD22, the human B cell line Daudi was stained
with a biotinylated polyacrylamide-based synthetic ligand
for mCD22 and hCD22, NeuGc2,6-PAA. Daudi cells
could only be stained with this probe after sialidase treat-
ment which led to unmasking of CD22. Pretreatment
with BPC-Neu5Ac was most potent in inhibiting the
binding of the synthetic CD22 ligand, confirming the se-
lective high affinity of this compound for hCD22 (Fig. 2).
When the same assay was performed on mouse B cells, 
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BPAc-Neu5Ac was the more potent inhibitor, confirming
the results of Fig. 1 and Table I. Sialidase treated mouse
CD22
 
 
 
/
 
 
 
 B cells could not be stained with NeuGc2,6-
PAA, showing the CD22 specificity of this synthetic
ligand (Fig. 2).
The potent and selective sialoside inhibitor BPC-
Neu5Ac allowed us to test directly in cellular signaling as-
says whether the Sia binding activity of CD22 is important
for its biological function. Since CD22 inhibits the BCR-
triggered Ca
 
2
 
 
 
 response, this response was analyzed in
Daudi cells. While stimulating Daudi cells with anti-IgM in
the presence of Me-Neu5Ac had no effect on the triggered
Ca
 
2
 
 
 
 response, pretreatment with BPC-Neu5Ac led to an
increase in the transient Ca
 
2
 
 
 
 peak (Fig. 3 A). Treatment
with this sialoside led to a clearly increased Ca
 
2
 
 
 
 response
also in anti-IgM stimulated primary human blood B lym-
phocytes (Fig. 3 B). The structurally highly similar com-
pound, but weaker inhibitor BPAc-Neu5Ac had no effect
on the Ca
 
2
 
 
 
 response in primary cells (Fig. 3 B) or in the
Daudi cell line (data not shown). This demonstrates that
the increased Ca
 
2
 
 
 
 flux is specific for BPC-Neu5Ac and
that a certain threshold affinity of the inhibitor for CD22 is
needed to observe the effect.
The next question was whether BPC-Neu5Ac treat-
ment interferes with CD22 phosphorylation. Fig. 4 shows
that anti-IgM treatment of Daudi cells in presence of
BPC-Neu5Ac led to a reduced tyrosine phosphorylation
of CD22, when compared with treatment with Me-
Neu5Ac. Me-Neu5Ac pretreatment served as a control,
because it gave identical CD22 activation as no pretreat-
ment in several experiments (data not shown). The presence
of BPC-Neu5Ac also led to less SHP-1 coprecipitation
with CD22 (Fig. 4). The weaker inhibitor BPAc-Neu5Ac
had no influence on tyrosine phosphorylation of hCD22
(data not shown). These results show that by disturbing the
ligand-binding domain the inhibitory function of CD22
can be reduced.
 
Discussion
 
This work describes the newly developed sialoside BPC-
Neu5Ac as a specific inhibitor for the ligand binding do-
main of hCD22. To unequivocally interpret our experi-
ments on B cell signaling in presence of BPC-Neu5Ac, it
was crucial to address the issue of specificity of this com-
pound. The high specificity of BPC-Neu5Ac for hCD22 is
supported by the following evidence: first, BPC-Neu5Ac
inhibited binding of hCD22-Fc to Sia containing target
cells very well, but not the binding of the closely related
Siglec-Fc proteins, mCD22-Fc, Sn-Fc, and MAG-Fc (data
not shown); second, BPC-Neu5Ac inhibited staining of
sialidase-treated human B cells with the synthetic CD22
ligand NeuGc2,6-PAA, while it had no effect on staining
of murine B cells. The specificity of the synthetic CD22
ligand for CD22 in this staining protocol was demonstrated
with murine wild-type and CD22
 
 
 
/
 
 
 
 B cells. A high spec-
ificity of the probe also for hCD22 is therefore very likely,
although other probe-binding receptors on human B cells
cannot be totally excluded; and third, a new crystal struc-
ture of BPC-Neu5Ac bound to Sn confirmed the pre-
dicted binding site to this Siglec (unpublished data). The
Figure 1. Inhibition of binding of CD22-Fc to target cells by synthetic
sialosides. (A) Structures of sialosides and abbreviations used in this study.
(B) Binding assays with human CD22. Binding of hCD22d1–3-Fc to mu-
rine AG8 cells was measured as described under Materials and Methods in
the presence of sialosides at the concentrations indicated.
 
Table I.
 
Comparison of Inhibitory Potential of Synthetic Sialosides
 
hCD22 mCD22 mSn
IC
 
50
 
 
 
M rIP IC
 
50
 
 
 
M rIP IC
 
50
 
 
 
M rIP
Me-Neu5Ac 1,400 1 4,689 1 884 1
BPAc-Neu5Ac 35 29 123 48 3,000 0.3
BPC-Neu5Ac 4 224 1,220 5 52 13
IC50-and rIP values of hCD22
 
d1–3
 
-Fc, mCD22
 
d1–3
 
-Fc, and mSn
 
d1–3
 
-Fc
were determined from three to six independent experiments. 
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higher affinity of BPC-Neu5Ac for hCD22 than for mSn
can be explained by molecular modeling of the CD22
binding site. The Val-109 and Leu-107 of Sn which make
contact to the biphenyl group of the sialoside are substi-
tuted by Arg-111 and Met-109 in hCD22. The biphenyl
substituent could be sandwiched between these two side
chains in hCD22 contributing a substantial binding affinity.
Together these data clearly suggest that the higher IgM
triggered Ca
 
2
 
 
 
 signal of BPC-Neu5Ac treated B cells is due
to a specific inhibition of the ligand-binding domain of
Figure 2. Specificity of the synthetic sialosides for
cellular CD22. Human Daudi cells, mouse C57BL/6
(B6), or mouse CD22 /  B cells were not pretreated
(black curves) or sialidase pretreated (all colored
curves), then incubated with no inhibitor (no inh., in
red) or the indicated inhibitors (same conc. used for
one type of cells) and afterwards stained with
NeuGc2,6-PAA. The assay shows inhibition of bind-
ing of NeuGc2,6-PAA (a synthetic CD22 ligand) to
hCD22 and mCD22 by the indicated sialosides. Mouse
cells are gated as B220 .
Figure 3. Presence of the sialoside BPC-Neu5Ac leads to increased BCR-triggered Ca2  responses. (A) Daudi B cells were stimulated with anti-IgM in
presence of either PBS, Me-Neu5Ac, or BPC-Neu5Ac at the given concentrations. (B) Human blood lymphocytes were stimulated with anti-IgM in pres-
ence of either PBS, Me-Neu5Ac, BPAc-Neu5Ac, or BPC-Neu5Ac (250  M each). CD20  gated cells are shown. Addition of antibody: at the vertical
lines. Horizontal lines are drawn for quantitative comparison. One typical experiment, out of five experiments (for A) or two experiments (for B) is shown. 
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CD22. This interference with ligand-binding leads to an
incomplete activation of the intracellular inhibitory domain
of CD22. From the data presented it is obvious that the
availability of 2,6Sia ligands on glycoproteins on the cellu-
lar surface is important for the function of this Siglec. B
cells usually display high levels of 2,6Sia on the surface (13,
14). Upon in vitro activation, a subset of human peripheral
B cells seems to downregulate surface expression of 2,6Sia
(13). This could be due to downregulation of the 
 
 
 
2,6 sia-
lyltransferase ST6GalI which is highly regulated in several
cell types (22) or activation of a sialidase (13). Thus, the in-
hibitory activity of CD22 could be regulated by the differ-
ential expression of 2,6Sia on the B cell surface. The inhib-
itor BPC-Neu5Ac most likely also affects the cellular
distribution of CD22 on the B cell membrane.
All available structural data show that the ligand-binding
domains of Siglecs are specific for the sialylated carbohy-
drate moieties with no involvement of the core protein in
binding (16). Also, recent surface plasmon resonance ex-
periments have shown that the affinity of CD22 for 2,6Sia,
coupled to different carriers, is very similar, irrespective of
whether the sugar is attached to different protein back-
bones or even polyacrylamide (Bakker, T., and A. van der
Merwe, personal communication). Thus, any glycoprotein
on the B cell surface containing 2,6Sia as terminal sugars
could be a potential ligand for CD22. Our Ca
 
2
 
 
 
 data argue
against the model that ligand binding of CD22 by other
surface glycoproteins sequesters CD22 away from the BCR
and thereby releases the BCR from CD22 inhibition (18).
In this case, interference with the ligand binding by sialo-
sides would release CD22 from this sequestering and lead
to its availability for BCR inhibition, resulting in a lower
Ca
 
2
 
 
 
 signal.
In contrast, our results support the model that the lectin
domain mediates CD22 interaction to specific transmem-
brane glycoprotein ligands which are positively involved in
BCR signaling. Such a specificity would be in contradic-
tion to the only carbohydrate-based binding specificity
mentioned above. But Sia-binding of CD22 could support
interaction to certain transmembrane proteins to which a
specific interaction is accomplished by other mechanisms.
Alternatively, CD22 binds to many glycoproteins, but the
ones which are abundant, structurally well accessible and
carry the highest level of appropriately linked Sia win.
There are two likely candidates as ligands for CD22: one is
membrane Ig. It has been shown that a low stochiometric
amount of CD22 can be coprecipitated with IgM from the
Figure 4. Lower tyrosine-phosphorylation of CD22 and less SHP-1 recruitment in presence of BPC-Neu5Ac. Daudi cells were stimulated with anti-IgM
in presence of Me-Neu5Ac (control) or BPC-Neu5Ac (both 250  M). Cells were lysed and immunoprecipitated with anti-CD22 plus anti-Vav1. The
anti-Vav1 I.P. served as loading control. (A) Immunoprecipitates were separated on a gel, blotted, and probed with the indicated blotting antibodies. The
membrane containing the largest fragments was reprobed with anti-CD22. (B) Densitometric analysis of band intensities of the gel. Western blots were
scanned and quantified. Intensities of P-tyr bands, or SHP-1 bands were divided by intensities of Vav1 bands. Vav1 was used as loading control, because
the anti-CD22 antibody showed interference with the first antibody. The calculated ratio of the highest activation (3 min, Me-Neu5Ac) was set at 100%.
Mean results from four experiments are shown ( SD). *P   0.05; **P   0.01 in Student’s t test.
Figure 5. Model of possible ligands for CD22 on the B cell surface. (A)
Interaction to surface Ig (BCR). (B) Interaction to CD45. Both CD22
interactions would be 2,6 Sia-dependent and could thus be inhibited by
BPC-Neu5Ac, leading to impairment of CD22 activation, SHP-1 re-
cruitment and a higher Ca2  flux. 
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B cell surface (23, 24). CD22 lectin binding to sialylated
membraneIgM may contribute to this constitutive associa-
tion (Fig. 5 A). Proximity to the BCR is likely to be crucial
for CD22 because the recruited SHP-1 needs to be near its
tyrosine phosphorylated substrates of the antigen receptor
signaling complex. A second likely candidate as CD22
ligand is CD45, since CD45 is an abundant protein on the
B cell surface, is highly glycosylated and has been detected
as a prominent ligand by immunoprecipitation with
CD22-Fc (25). Also, CD45 is known to activate lyn, the
src-like kinase responsible for CD22 phosphorylation (26)
(Fig. 5 B). After initial binding to CD45, CD22 could sub-
sequently interact with the BCR or even recruit CD45 to
the BCR. These possibilities will be directly tested in fu-
ture experiments. Additionally to the discussed cis-binding,
trans interactions of CD22 to ligands on adjacent cells can-
not be excluded. Such interactions which may relieve the
B cell from CD22 suppression, could be relevant when B
cells are closely packed together such as in primary follicles
(5, 18). Recently, it was shown that trans interactions of
CD22 with ligands on target cells can also influence Ag-
specific B cell activation (27).
In summary, we have described a novel role for the
CD22-lectin domain. Binding to ligands on the cell sur-
face apparently supports the inhibitory function of CD22
on BCR-triggered Ca
 
2
 
 
 
 flux. Our data are very well com-
patible with the study of Jin et al. (28) who have come to
similar conclusions with a completely different experimen-
tal approach. In addition to addressing the biological role
of the adhesion domain of CD22, the newly described
sialoside could be potentially very important also therapeuti-
cally. Application of this structurally simple compound
leads to an enhanced B cell response, which could be valu-
able for immunocompromised patients. Oligomerization
of the sialoside can easily be used in the future to enhance
affinity and avidity and improve the biological efficacy
even further.
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